Form 8-K - Current report:
SEC Accession No. 0001193125-25-141090
Filing Date
2025-06-16
Accepted
2025-06-16 07:02:35
Documents
13
Period of Report
2025-06-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d75328d8k.htm   iXBRL 8-K 41201
2 EX-99.1 d75328dex991.htm EX-99.1 18884
  Complete submission text file 0001193125-25-141090.txt   185775

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA me-20250613.xsd EX-101.SCH 2502
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE me-20250613_lab.xml EX-101.LAB 18008
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE me-20250613_pre.xml EX-101.PRE 11252
15 EXTRACTED XBRL INSTANCE DOCUMENT d75328d8k_htm.xml XML 3778
Mailing Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102
Business Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102 (650) 938-6300
23andMe Holding Co. (Filer) CIK: 0001804591 (see all company filings)

EIN.: 871240344 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-39587 | Film No.: 251048516
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)